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Table S1. Calculated binding energy for the rimonabant and 16 MSC compounds.  
 


























Figure S1. CB1-rimonabant pharmacophores with side chains important for receptor-ligand 
interactions labeled.  (A) Lange and Kruse published a pharmacophore 
1
 based on prior docking 
studies 
2-5
 involving the human CB1 receptor predicted using homology modeling with bRho.  
These studies find that rimonabant forms one hydrogen bond with K3.28 and sandwiches W5.43. 
(B) Our predicted pharmacophore shows that rimonabant has a different binding site in our 
GEnSeMBLE-derived CB1 structure that allows it to form two hydrogen bonds, including one 
with W5.43, and have strong aromatic interactions with the receptor.  Residues in the binding 
site are labeled in both Figures S1A and S1B.  Residues labeled in red in Figure S1B are unique 
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